Syneos Health has announced that it has expanded its relationship with Komodo Health. The expanded partnership builds on two-years of previous collaboration between Syneos Health and Komodo Health, which began with data-driven strategies to enhance customer engagement for the Syneos Health Kinetic team. This will allow Syneos Health to analyze clinical, real-world, and commercial data, offering customers integration to their operational trial designs and commercialization deployment strategies.
Syneos Health will use Komodo Health’s Prism software to support feasibility, market sizing, site selection and patient cohort analytics. Additionally, Komodo’s Sentinel solution will provide a comprehensive view into real-world patient journeys and enable the integration of proprietary datasets, tools and algorithms to derive insights.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.